Devimistat Receives FDA Fast Track Designation for AML
Devimistat Receives FDA Fast Track Designation for AML Jorge Cortes, MD Georgia Cancer Center #AML #Cancer #Research
Link To FULL Video:
https://www.oncologytube.com/video/39776/jorge-cortes-md-gcc_cortes-gacancercenter-aml-cancer-research-devimistat-receives-fda-fast-track-designation-for-aml
Видео Devimistat Receives FDA Fast Track Designation for AML канала OncologyTube
Link To FULL Video:
https://www.oncologytube.com/video/39776/jorge-cortes-md-gcc_cortes-gacancercenter-aml-cancer-research-devimistat-receives-fda-fast-track-designation-for-aml
Видео Devimistat Receives FDA Fast Track Designation for AML канала OncologyTube
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
LBA-1 Driver Mutation Acquisition in Utero and Childhood
Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer
ASCO 2021 Highlights in Breast Cancer Aditya Bardia, MD
Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Blastic Plasmacytoid Dendritic Cell Neoplasm
Real World Outcomes and Prognostication of Older PCNSL in the Contemporary Era
Liquid biopsies timely and effective testing method for NSCLC patients in Canada
Postmenopausal Women With Early-stage Breast Cancer and Low Recurrence Score
European Commission Approves Avelumab for mUC
Lung-Map Translational Discoveries Shared At 2020 World Conference On Lung Cancer
SY-1425, a Potent and Selective RARα Agonist
Amivantamab, an EGFR-MET bispecific antibody, in combination with lazertinib in advanced EGFR NSCLC
VS-6766, a unique inhibitor of the RAF/MEK signaling pathway for patients with KRAS mutant tumors
A phase 1 study of AMG 757
New Data For In Metastatic, Squamous Cell Carcinoma Of The Lung
ASCO 2021 Highlights in Colorectal Cancer and Gastrointestinal Cancer David Illson, MD
Medical Marijuana associated with fewer hospitalizations for individuals with sickle cell disease
Ibrutinib U.S. Prescribing Information Updated to Include Long-Term Data for WM
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens
Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity